•
Mar 31
•/
Canopy Growth Q4 2025 Earnings Report
Canopy Growth reported a net loss of $221.5 million and revenue of $65.0 million in Q4 2025.
Key Takeaways
Canopy Growth faced an 11% revenue decline in Q4 2025 compared to the same period last year, primarily due to weaker international and Storz & Bickel sales. Despite this, the company made progress in reducing operating losses and continues executing on cost-saving strategies.
Canopy Growth
Canopy Growth
Canopy Growth Revenue by Segment
Canopy Growth Revenue by Geographic Location
Forward Guidance
The company plans to accelerate growth in global medical cannabis, streamline Canadian adult-use operations, and launch new Storz & Bickel products while targeting positive Adjusted EBITDA.
Positive Outlook
- Global medical cannabis operations unified under one business unit
- Focus on high-margin, high-THC formats in Canada
- Targeting improved gross margin and profitability
- Expected annualized cost savings of $20M from SG&A and COGS reductions
- Launch of new Storz & Bickel device expected later in FY2026
Challenges Ahead
- Ongoing macroeconomic uncertainty
- Soft consumer demand for vaporizers
- Regulatory challenges in markets like Poland
- Declines in Australia medical cannabis sales
- Continued negative free cash flow in Q4
Revenue & Expenses
Visualization of income flow from segment revenue to net income